SCHEMBL6771987

SCHEMBL6771987

CCOC=CCc1ccccc1[N+](=O)[O-]

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.47
TSHR P16473 1/20 0.47
HPGD P15428 1/20 0.44
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
HTT P42858 1/20 0.41
RAB9A P51151 2/20 0.41
MAOB P27338 1/20 0.41
LMNA P02545 1/20 0.40
ACHE P22303 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
BCHE P06276 1/20 0.40
HSD17B10 Q99714 1/20 0.40
KDM4E B2RXH2 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
MAPK1 P28482 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
NPC1 O15118 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3071789 0.84 ALDH1A1 (0.50) ALDH1A1TSHRHPGDMEN1KMT2A
SCHEMBL7528501 0.79 ALDH1A1 (0.55) ALDH1A1TSHRHPGDMEN1KMT2A
SCHEMBL8060690 0.76 ALDH1A1 (0.42) ALDH1A1TSHRHPGDMEN1KMT2A
SCHEMBL10369182 0.76 ALDH1A1 (0.55) ALDH1A1TSHRHPGDMEN1KMT2A
SCHEMBL3335582 0.76 ALDH1A1 (0.55) ALDH1A1TSHRHPGDMEN1KMT2A
SCHEMBL29032830 0.76 ALDH1A1 (0.55) ALDH1A1TSHRHPGDMEN1KMT2A
SCHEMBL6158455 0.76 ALDH1A1 (0.55) ALDH1A1TSHRHPGDMEN1KMT2A
SCHEMBL28940904 0.76 ALDH1A1 (0.55) ALDH1A1TSHRHPGDMEN1KMT2A
SCHEMBL28940902 0.76 ALDH1A1 (0.55) ALDH1A1TSHRHPGDMEN1KMT2A
SCHEMBL3258912 0.76 ALDH1A1 (0.55) ALDH1A1TSHRHPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6787534-B2 SUBSTITUTED QUINOLINE AND ISOQUINOLINE ANTIANGIOGENIC AGENTS; SULFONYLUREAS EISAI CO., LTD. (JP) 2004-09-07 US disclosed
US-20030144507-A1 Sulfonamide-containing heterocyclic compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2003-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144507-A1 Sulfonamide-containing heterocyclic compounds SLC5A2, SLC5A1, CBR3 ALDH1A1 1018/4885TSHR 1543/4885HPGD 2152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.